Challenges of advanced hepatocellular carcinoma (Q28076867)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

24 March 2020

review article

1 reference

title

Challenges of advanced hepatocellular carcinoma (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

24 March 2020

main subject

hepatocellular carcinoma

1 reference

3 April 2019

1 reference

3 April 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

24 March 2020

Cosimo Nardi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

24 March 2020

Fabio Marra

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

24 March 2020

author name string

Andrea L Inghilesi

2

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

24 March 2020

Sami Aburas

3

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

24 March 2020

Gian G Taliani

4

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

24 March 2020

language of work or name

1 reference

1 September 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

World Journal of Gastroenterology

24 March 2020

published in

3 references

3 April 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

24 March 2020

volume

22

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

24 March 2020

issue

34

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

24 March 2020

page(s)

7645-7659

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 4.0 International

24 March 2020

copyright license

1 reference

on focus list of Wikimedia project

3 April 2019

ScienceSource

0 references

cites work

Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Nutritional support for liver disease

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Sorafenib in advanced hepatocellular carcinoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Supportive care for patients with gastrointestinal cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

The global health burden of infection-associated cancers in the year 2002

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

7 April 2017

Hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Toxicity and response criteria of the Eastern Cooperative Oncology Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Assessment of radiologic response to targeted therapies in patients with hepatocellular carcinoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Systematic review: the treatment of muscle cramps in patients with cirrhosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Hepatocellular carcinoma: clinical frontiers and perspectives

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Pre-, peri-, and postoperative oral administration of branched-chain amino acids for primary liver cancer patients for hepatic resection: a systematic review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Response criteria in oncologic imaging: review of traditional and new criteria

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Sleep-wake abnormalities in patients with cirrhosis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Review article: prescribing medications in patients with cirrhosis - a practical guide

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Shaping the future management of hepatocellular carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Physiologic and laboratory correlates of depression, anxiety, and poor sleep in liver cirrhosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Differential effects of exercise on cancer-related fatigue during and following treatment: a meta-analysis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Comparison of differences and determinants between presence and absence of sleep disturbance in hepatocellular carcinoma patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Treatment Planning and Volumetric Response Assessment for Yttrium-90 Radioembolization: Semiautomated Determination of Liver Volume and Volume of Tumor Necrosis in Patients with Hepatic Malignancy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Resear

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Diffusion-weighted MR imaging of the liver.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Molecular targeted therapies in hepatocellular carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Radiologic findings following Y90 radioembolization for primary liver malignancies.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Response evaluation of gastrointestinal stromal tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Quantitative assessment of colorectal cancer tumor vascular parameters by using perfusion CT: influence of tumor region of interest.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Efficacy of percutaneous cementoplasty for bone metastasis from hepatocellular carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Liver cancer and its prevention.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Hospice palliative care for patients with hepatocellular carcinoma in Taiwan

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Hepatocellular carcinoma in Central Europe: prognostic features and survival

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Transection of the oesophagus for bleeding oesophageal varices

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Immune Checkpoint Blockade in Hepatocellular Carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Active at night, sleepy all day--sleep disturbances in patients with hepatitis C virus infection

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

2 June 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Shape-constraint region growing for delineation of hepatic metastases on contrast-enhanced computed tomograph scans

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Subtype differentiation of renal cell carcinoma using diffusion-weighted and blood oxygenation level-dependent MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

The mediating effects of depression on sleep disturbance and fatigue: symptom clusters in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Baclofen for the treatment of muscle cramps in patients with cirrhosis: A new alternative

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V22.I34.7645

Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5016365

Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma

27 November 2018

1 reference

12 December 2020

Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma

1 reference

12 December 2020

Fluoxetine disposition and elimination in cirrhosis

1 reference

12 December 2020

Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study

1 reference

12 December 2020

Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib

1 reference

12 December 2020

Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma

1 reference

12 December 2020

Pharmacokinetics of paroxetine in patients with cirrhosis

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V22.I34.7645

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

24 March 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27678348 AND SRC:MED&resulttype=core&format=json

24 March 2020

PubMed publication ID

27678348

2 references